8-K

a50149901.htm

PFIZER INC. 8-K

UNITED

STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of report (Date of earliest event reported): January 31, 2012

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other jurisdiction

of incorporation)

(Commission File

Number)

(I.R.S. Employer

Identification No.)

235 East 42nd Street

New York, New York

10017

(Address

of principal

executive

offices)

(Zip

Code)

Registrant s telephone number, including area code:

(212)

733-2323

Not Applicable

(Former Name or Former Address,

if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On January 31, 2012, Pfizer Inc. ( Pfizer ) issued a press release

announcing its financial results for fourth-quarter and full-year 2011.

The information contained in the press release is deemed to be filed

under the Securities Exchange Act of 1934 as Exhibit 99 to this report,

and such press release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit 99

Press Release of Pfizer Inc. dated January 31, 2012, reporting

Pfizer's financial results for fourth-quarter and full-year 2011.

Exhibit 99 is deemed to be filed under the Securities Exchange

Act of 1934 in this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the

registrant has caused this report to be signed on its behalf by the

authorized undersigned.

PFIZER INC.

By:

/s/ Matthew Lepore

Matthew Lepore

Vice President and Corporate Secretary

Chief Counsel Corporate Governance

Dated:

January 31, 2012

EXHIBIT INDEX

Exhibit No.

Description

99

Press Release of Pfizer Inc. dated January 31, 2012, reporting

Pfizer's financial results for fourth-quarter and full-year 2011.

-->